CXCL10-based diagnosis and treatment of respiratory illnesses
AssigneeUniversity Health Network
InventorsDavid Kelvin, Mark Cameron, Desmond Persad
Life of this patent
Estimating the term…
Abstract
Elevated blood levels of the chemokine CXCL10 polypeptide are associated with respiratory illnesses (e.g. SARS, influenza and community-acquired pneumonia) and are useful in diagnosis of patients. Methods are provided for diagnosis and treatment of patients suffering from respiratory illnesses. Methods are provided for identifying inhibitors of the CXCL10:CXCR3 axis, for use in treating patients suffering from respiratory illnesses.
Claims58
A method for diagnosing respiratory illness in a patient, the method comprising detecting CXCL10 polypeptide in a biological sample from a patient, wherein an elevated level of CXCL10 polypeptide in said sample relative to a healthy control is diagnostic or prognostic of respiratory illness.
A method for monitoring the course of treatment of a patient suffering from respiratory illness, the method comprising:
- (a) detecting CXCL10 polypeptide in a biological sample obtained from a patient undergoing treatment for respiratory illness, wherein an elevated level of CXCL10 polypeptide in said sample relative to a healthy control is diagnostic or prognostic of respiratory illness;
- and
- (b) repeating step (a) at intervals of time so as to monitor the course of treatment of the patient.
A commercial package comprising means for detecting CXCL10 polypeptide in a biological sample from a patient, together with instructions for use for diagnosis and/or prognosis of respiratory illness in a patient or for monitoring treatment thereof.
Use of CXCL10 polypeptide in the diagnosis of respiratory illness, wherein said CXCL10 polypeptide is contained in a biological sample from a patient and wherein an elevated level of CXCL10 polypeptide in said sample relative to a healthy control is diagnostic or prognostic of respiratory illness.
A method for treating a patient suffering from respiratory illness, the method comprising administering a compound that inhibits the CXCL10:CXCR3 axis.
A method for identifying a therapeutic agent for treating a respiratory illness, the method comprising:
- (a) providing a test compound;
- (b) providing a cell that expresses a polypeptide selected from CXCL10 polypeptide and CXCR3 polypeptide when cultured under suitable conditions in vitro;
- and
- (c) detecting whether the test compound inhibits expression of said polypeptide by said cell.
A method for identifying a therapeutic agent for treating respiratory illness, the method comprising:
- (a) providing a test compound;
- (b) providing a polypeptide selected from CXCL10 polypeptide or CXCR3 polypeptide;
- and
- (c) detecting whether the test compound binds to said polypeptide.
A method for identifying a therapeutic agent for treating respiratory illness, the method comprising:
- (a) providing a test compound;
- (b) providing a polypeptide selected from CXCL10 polypeptide or CXCR3 polypeptide;
- (c) providing a binding partner that binds to said polypeptide;
- and
- (d) detecting whether the test compound inhibits the interaction between said binding partner and said polypeptide.
Dependencies are inferred from the claim text.